CSL Limited

ASX:CSL Voorraadrapport

Marktkapitalisatie: AU$59.8b

CSL Toekomstige groei

Future criteriumcontroles 3/6

CSL zal naar verwachting groeien in winst en omzet met respectievelijk 28.1% en 4.4% per jaar. De winst per aandeel zal naar verwachting groeien met 27.6% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 17.1% zijn.

Belangrijke informatie

28.1%

Groei van de winst

27.58%

Groei van de winst per aandeel

Biotechs winstgroei29.8%
Inkomstengroei4.4%
Toekomstig rendement op eigen vermogen17.10%
Dekking van analisten

Good

Laatst bijgewerkt28 Apr 2026

Recente toekomstige groei-updates

Recent updates

CSL: Manufacturing Expansion And CEO Transition Will Support Long Term Share Rebound

The CSL analyst price target has been trimmed by about A$9, as analysts now factor in slightly lower revenue growth, a modestly softer profit margin outlook, a marginally higher discount rate and a small reset in assumed future P/E multiples. Analyst Commentary Recent Street research on CSL and peers points to a mixed but useful read on how analysts are thinking about valuation, execution risk and growth expectations.

CSL: Manufacturing Expansion And CEO Transition Will Support Future Share Recovery

Analysts have slightly increased CSL's fair value estimate to A$208.11, citing modest adjustments to the discount rate, revenue growth, profit margin and a higher assumed future P/E multiple as they reassess the stock following recent rating changes. Analyst Commentary Recent rating actions around CSL highlight a split in views on how much investors should pay for the stock at this stage, which feeds directly into the updated fair value estimate of A$208.11.

CSL: Manufacturing Expansion And Horizon 2 Rollout Will Support Future Share Recovery

Narrative Update on CSL Analysts have adjusted CSL's fair value estimate from A$205.16 to A$207.81. This reflects updated views on its discount rate, revenue growth, profit margins and future P/E assumptions, alongside recent mixed rating actions on the stock.

CSL: Manufacturing Expansion And Leadership Transition Will Support Future Share Recovery

Analysts have trimmed their CSL price target by about A$6 to reflect slightly lower long term fair value estimates, modestly higher discount rates and more conservative assumptions for revenue growth and profit margins, partially offset by a higher future P/E multiple. Analyst Commentary Recent Street research around CSL points to a mixed setup, with some firms taking a more constructive stance and others turning cautious.

CSL: The Dip Is the Opportunity

CSL: The Dip Is the Opportunity Most people look at CSL's stock chart right now and see a problem. Down 35% from its highs, margins cut in half, and a company in the middle of its biggest restructuring in decades.

CSL: Execution On Gene Therapy And Leadership Transition Will Support Share Recovery

Analysts have trimmed their CSL fair value estimate to A$210.90 from A$228.58 as updated assumptions on discount rate, revenue growth, profit margins and future P/E feed through into a lower overall price target. Analyst Commentary Recent research views on CSL have been mixed, with some analysts turning more cautious while others have taken a more constructive stance at different points.

My view on CSL Limited is positive. It’s a high-quality growth stock with strong barriers to entry through its global plasma network.

One stock I find particularly compelling is CSL Limited (ASX: CSL), primarily due to its strong competitive positioning, structural growth drivers, and valuation complexity. From a fundamental perspective, CSL operates in the global plasma therapies and specialty pharmaceuticals market, where demand is relatively inelastic and supported by long-term healthcare trends.

CSL's (ASX:CSL) Soft Earnings Are Actually Better Than They Appear

Feb 17
CSL's (ASX:CSL) Soft Earnings Are Actually Better Than They Appear

CSL: Share Recovery Will Be Supported By Execution And Recent Upgrade

Analysts have trimmed their fair value estimate for CSL to about A$228.58 from A$232.54, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E expectations. Analyst Commentary Recent Street research on CSL points to a mix of optimism and caution, which helps explain the modest trim in fair value.

Seqirus Demerger And Cost Savings Will Shape A Steady Long Term Outlook

Catalysts About CSL CSL is a global biopharmaceutical group focused on plasma therapies, vaccines and specialty medicines addressing rare and serious diseases. What are the underlying business or industry changes driving this perspective?

CSL: Share Recovery Will Be Driven By Seqirus Reset And Demerger Deferral

Analysts have raised their fair value target for CSL to A$232.54. This reflects slightly adjusted assumptions for revenue growth, profit margins and future P/E multiples after recent upgrades and renewed interest in the shares.

CSL: Shares Will Recover As Seqirus Reset And Demerger Deferral Settle

Analysts have trimmed their CSL price target slightly, with fair value moving from about A$236.57 to A$232.45, as they factor in softer Seqirus vaccination trends and the deferred vaccine demerger, while still seeing the recent share pullback as an opportunity to re-engage with the stock. Analyst Commentary Recent research on CSL focuses heavily on the updated outlook for Seqirus, the indefinitely deferred vaccine demerger, and where the current share price sits relative to revised fair value estimates.

CSL: Shares Will Recover As Seqirus Drag Fades After AGM Downgrade

Analysts have nudged down their price target on CSL by A$5 to reflect slightly softer long term revenue growth assumptions and a modestly higher discount rate, even as they highlight resilient margins and view the recent selloff as an opportunity to re engage with the shares. Analyst Commentary Recent commentary around CSL reflects a more constructive stance on the stock despite near term earnings noise, with valuation support emerging after the sharp pullback.

CSL: Shares Will Recover As Seqirus Headwinds Ease After Recent Pullback

Analysts have trimmed their price target on CSL slightly, from about A$230 to A$225, reflecting tempered expectations for Seqirus amid weaker U.S. vaccination trends and the indefinite deferral of the planned vaccine business demerger, even as they note that the recent share price correction has opened a more attractive entry point. Analyst Commentary Analyst views on CSL have turned more constructive following the share price pullback, even as earnings expectations have been nudged lower to reflect the softer outlook for Seqirus.

CSL: Share Price Will Rebound After Vaccine Demerger Deferral And Segment Headwinds

Analysts have marginally increased their fair value estimate for CSL from $246.49 to $246.96. This reflects a cautiously optimistic outlook as concerns over segment performance and revised vaccination forecasts are balanced by expectations of a market overreaction and longer-term recovery potential.

CSL: Share Price Correction Will Present Opportunity As Vaccine Uncertainty Eases

CSL's analyst price target has been lowered from A$280.61 to A$246.49, reflecting analysts' revised expectations following recent updates about weaker revenue growth, a more cautious profit margin outlook, and continued challenges in key business units. Analyst Commentary Market analysts have offered mixed perspectives on CSL following recent trading updates and management commentary, resulting in shifts in both ratings and price targets.

Analysts Adjust CSL Outlook as Valuation Rises Amid Mixed Market Sentiment and Company Updates

CSL's fair value estimate has increased modestly by $0.23 to $280.61, as analysts factor in softened revenue and profit margin assumptions in light of near-term challenges in end-market demand and distributor activity. Analyst Commentary Recent street research reflects both cautious and optimistic views toward CSL's near-term execution and longer-term prospects.

Operational Improvements Will Unlock Biotech Potential And China Market Expansion

The analyst consensus price target for CSL has been revised downward by 1.5% to $280.38. Analysts cite near-term uncertainties in end-market demand and distribution dynamics as key factors in the updated valuation.

CSL Limited's (ASX:CSL) Share Price Not Quite Adding Up

Sep 25
CSL Limited's (ASX:CSL) Share Price Not Quite Adding Up

Operational Improvements Will Unlock Biotech Potential And China Market Expansion

Despite the consensus Analyst Price Target for CSL remaining largely unchanged, the significant increase in Future P/E from 26.27x to 40.16x indicates investor expectations for higher earnings growth or a premium valuation, resulting in only a marginal fair value decrease to A$284.79. What's in the News CSL plans to demerge its influenza vaccine division, CSL Seqirus, into a separately listed company by end of FY26, along with job cuts and a share repurchase program to allow strategic autonomy.

Advancements In iNOMi Technology And HEMGENIX Will Strengthen Market Position

CSL's consensus price target has been revised downward, reflecting a material drop in expected revenue growth alongside a sharply higher future P/E ratio, with fair value now set at A$291.99. What's in the News CSL expects group revenue growth of approximately 4-5% and NPATA growth of 7-10% for FY26, excluding non-recurring restructuring costs.

Is CSL Limited (ASX:CSL) Trading At A 43% Discount?

Aug 07
Is CSL Limited (ASX:CSL) Trading At A 43% Discount?

Here's Why CSL (ASX:CSL) Can Manage Its Debt Responsibly

Jun 14
Here's Why CSL (ASX:CSL) Can Manage Its Debt Responsibly

CSL is undervalued in High Tax Scenario

CSL Behring: This is CSL's largest segment and the global leader (#1) in plasma therapies within an estimated US$30 billion industry.11 It focuses on researching, developing, manufacturing, and distri
User avatar

Advancements In iNOMi Technology And HEMGENIX Will Strengthen Market Position

Advancements in plasma collection and operational efficiencies are set to reduce costs and improve CSL Behring's margins, potentially boosting overall earnings.

Winst- en omzetgroeiprognoses

ASX:CSL - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
6/30/202817,0713,5413,4094,47015
6/30/202716,3553,2873,3224,23316
6/30/202615,7671,3843,0593,42316
12/31/202515,4071,3962,4833,604N/A
9/30/202515,4832,1992,5233,583N/A
6/30/202515,5583,0022,5633,561N/A
3/31/202515,3942,8752,2153,258N/A
12/31/202415,2302,7481,8672,954N/A
9/30/202415,0152,6951,6882,859N/A
6/30/202414,8002,6421,5082,764N/A
3/31/202414,4902,5571,3332,727N/A
12/31/202314,1792,4721,1582,690N/A
9/30/202313,7452,3331,0342,646N/A
6/30/202313,3102,1949092,601N/A
3/31/202312,5072,1567652,392N/A
12/31/202211,7052,1186222,182N/A
9/30/202211,1332,1861,0012,406N/A
6/30/202210,5622,2551,3812,629N/A
3/31/202210,5872,2901,2512,679N/A
12/31/202110,6122,3251,1212,728N/A
9/30/202110,4612,3501,5383,175N/A
6/30/202110,3102,3751,9553,622N/A
3/31/202110,1452,5202,1273,597N/A
12/31/20209,9802,6652,2993,571N/A
9/30/20209,5652,3841,7103,030N/A
6/30/20209,1512,1031,1212,488N/A
3/31/20209,0482,0541,0092,418N/A
12/31/20198,9442,0068972,347N/A
9/30/20198,7421,962N/A1,996N/A
6/30/20198,5391,919N/A1,644N/A
3/31/20198,4061,861N/A1,621N/A
12/31/20188,2741,803N/A1,597N/A
9/30/20188,0941,766N/A1,750N/A
6/30/20187,9151,729N/A1,902N/A
3/31/20187,6661,674N/A1,662N/A
12/31/20177,4171,618N/A1,422N/A
9/30/20177,1821,478N/A1,335N/A
6/30/20176,9471,337N/A1,247N/A
3/31/20176,8021,333N/A1,192N/A
12/31/20166,6561,329N/A1,138N/A
9/30/20166,3861,286N/A1,158N/A
6/30/20166,1151,242N/A1,179N/A
3/31/20165,9831,324N/A1,296N/A
12/31/20155,8501,406N/A1,413N/A
9/30/20155,6541,392N/A1,388N/A
6/30/20155,4591,379N/A1,364N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei CSL ( 28.1% per jaar) ligt boven de spaarquote ( 3.5% ).

Winst versus markt: De winst van CSL ( 28.1% per jaar) zal naar verwachting sneller groeien dan de Australian markt ( 12% per jaar).

Hoge groeiwinsten: De winst van CSL zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van CSL ( 4.4% per jaar) zal naar verwachting langzamer groeien dan de markt Australian ( 6.4% per jaar).

Hoge groei-inkomsten: De omzet van CSL ( 4.4% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen CSL zal naar verwachting over 3 jaar laag zijn ( 17.1 %).

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/05/03 21:59
Aandelenkoers aan het einde van de dag2026/05/01 00:00
Inkomsten2025/12/31
Jaarlijkse inkomsten2025/06/30

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

CSL Limited wordt gevolgd door 27 analisten. 16 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Saul HadassinBarrenjoey Markets Pty Limited
Thomas WakimBell Potter
Lyanne HarrisonBofA Global Research